|1.||Li, Yan: 16 articles (09/2015 - 06/2002)|
|2.||Liu, Geng-Tao: 6 articles (06/2009 - 06/2004)|
|3.||Liu, Geng Tao: 5 articles (01/2009 - 08/2005)|
|4.||Sheng, Li: 4 articles (09/2015 - 11/2008)|
|5.||Zhao, Jing: 4 articles (05/2010 - 05/2008)|
|6.||Chen, Hui: 3 articles (09/2015 - 05/2008)|
|7.||Xia, Qiang: 3 articles (07/2015 - 08/2009)|
|8.||Sun, Hua: 3 articles (01/2012 - 05/2006)|
|9.||Yao, Xiao-Min: 3 articles (05/2010 - 07/2009)|
|10.||Liu, Yan-Hong: 2 articles (10/2015 - 06/2011)|
|1.||Chronic Hepatitis B
04/01/2012 - "[Efficacy of combination therapy with peginterferon alfa-2alpha and bicyclol in chronic hepatitis B with high ALT levels]."
01/01/2006 - "To study the benefits and harms of bicyclol for patients with chronic hepatitis B. "
09/01/2005 - "[Histological study of livers from the patients with chronic hepatitis B treated with bicyclol]."
02/01/2008 - "To investigate the relationship between the genetic polymorphisms of CYP3A5 and the clinical effectiveness of Bicyclol on patients with chronic hepatitis B to make individual medication possible. "
02/01/2008 - "[Relationship between the genetic polymorphism of CYP3A5 gene and the clinical response to bicyclol in chronic hepatitis B]."
05/01/2015 - "Bicyclol plus lifestyle intervention was effective for chronic hepatitis B combined fatty liver patients with poor biochemical responses."
01/01/2008 - "Bicyclol (150 and 300 mg x kg(-1)) provided significant protection against fatty liver by inhibiting the elevation of hepatic TG and CHO, adjusting abnormal serum lipids, inhibiting the elevation of serum ALT, AST, and ameliorating the severity of pathological changes. "
07/10/2009 - "The present study was performed to further investigate the effect of bicyclol on tetracycline-induced fatty liver and related mechanism in mice. "
05/01/2015 - " patients complicated with fatty liver were treated with bicyclol tablets (25 mg, t.i.d) additional consecutive 48 weeks. "
07/10/2009 - "Protective effect of bicyclol on tetracycline-induced fatty liver in mice."
|3.||Liver Cirrhosis (Hepatic Cirrhosis)
06/21/2015 - "Bicyclol significantly attenuates BDL-induced liver fibrosis by reversing fibrogenic gene expression. "
06/21/2015 - "Treatment with bicyclol significantly reduced liver fibrosis and bile duct proliferation after BDL. "
05/01/2010 - "As a result, bicyclol significantly protected against BSA-induced liver fibrosis as evidenced by the reduction of elevated serum HA, PIIIP, and hepatic Hyp in rats, while liver pathological changes were also alleviated. "
05/01/2010 - "Effects of bicyclol on immunological liver fibrosis in rats."
12/17/2004 - "To study the protective effects and related mechanism of bicyclol on liver fibrosis induced by carbon tetrachloride (CCl(4)). "
06/01/2002 - "The protective effects of bicyclol on kidney injury induced by ischemia-reperfusion are dose-dependent. "
08/01/2009 - "The purpose of this study was to investigate the effect of bicyclol on hepatic ischemia/reperfusion (I/R) injury and related mechanisms. "
08/07/2009 - "After 6h of bicyclol pretreatment on the third day, forebrain ischemia was induced for 1h by bilateral occlusion of the carotid arteries. "
08/07/2009 - "To assess its potential neuroprotective effect against ischemia/reperfusion (IR) injury in mice, bicyclol was administered intragastrically once a day for 3 days. "
08/07/2009 - "Bicyclol attenuates oxidative stress and neuronal damage following transient forebrain ischemia in mouse cortex and hippocampus."
01/01/2009 - "Bicyclol: a novel drug for treating chronic viral hepatitis B and C."
09/01/2005 - "Thirty one patients with chronic viral hepatitis B were divided into two groups and were treated with bicyclol orally at doses of 150 mg daily or 75 mg daily for 36 weeds. "
09/01/2005 - "To study histological changes of the livers in patients with chronic viral hepatitis B treated with bicyclol tablets. "
12/01/2007 - "To analyze the efficacy and safety of bicyclol combined with thymosin in treatment of chronic viral hepatitis B (CHB). "
12/01/2007 - "[Effectiveness and safety of bicyclol combined with thymosin in treatment of chronic viral hepatitis B]."
|2.||Carbon Tetrachloride (Tetrachloromethane)
|4.||Alanine Transaminase (SGPT)
|5.||adefovir dipivoxil (Hepsera)
|6.||Potassium Channels (Potassium Channel)
|9.||Hepatitis B e Antigens